Exemptia
Prescription
Biologic (TNF-alpha Inhibitor)
Adalimumab Injection (Biosimilar)
Manufacturer: Zydus Cadila
Description
Exemptia is Zydus Cadila's biosimilar adalimumab — the world's first biosimilar adalimumab, launched in India. A fully human monoclonal antibody that neutralises TNF-alpha. Used for psoriasis, psoriatic arthritis, and hidradenitis suppurativa. Significantly more affordable than the originator Humira.
Active Compounds
No tracked compounds
Indications
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
- Hidradenitis suppurativa
Dosage
80mg subcutaneous injection at week 0, then 40mg every other week starting at week 1.
Formulations
Full Ingredient List
- Adalimumab
- Mannitol
- Citric Acid Monohydrate
- Sodium Citrate
- Disodium Hydrogen Phosphate Dihydrate
- Sodium Dihydrogen Phosphate Dihydrate
- Sodium Chloride
- Polysorbate 80
- Water for Injection
Side Effects
- Injection site reactions
- Upper respiratory infections
- Reactivation of tuberculosis
- Hepatotoxicity
- Demyelinating disorders (rare)
Warnings
- Screen for latent tuberculosis before starting (mandatory in India)
- Treat latent TB with isoniazid before starting biologic
- Avoid in active infections
- Increased lymphoma risk (theoretical)
- Avoid live vaccines
- Monitor for signs of heart failure